Cargando…
High Sensitivity C Reactive Protein in Patients with Rheumatoid Arthritis Treated with Antibodies against IL-6 or Jak Inhibitors: A Clinical and Ultrasonographic Study
Background: We examined whether high-sensitivity CRP (hsCRP) reflected the inflammatory disease status evaluated by clinical and ultrasound (US) parameters in RA patients receiving IL-6 receptor antibodies (anti-IL-6R) or JAK inhibitors (JAKi). Methods: We conducted a cross-sectional study of patien...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8774492/ https://www.ncbi.nlm.nih.gov/pubmed/35054349 http://dx.doi.org/10.3390/diagnostics12010182 |
_version_ | 1784636359926874112 |
---|---|
author | Frade-Sosa, Beatriz Ponce, Andrés Ruiz-Esquide, Virginia García-Yébenes, Maria Jesús Morlá, Rosa Sapena, Nuria Ramirez, Julio Azuaga, Ana Belen Sarmiento, Juan Camilo Cañete, Juan D. Gomez-Puerta, Jose A. Sanmarti, Raimon |
author_facet | Frade-Sosa, Beatriz Ponce, Andrés Ruiz-Esquide, Virginia García-Yébenes, Maria Jesús Morlá, Rosa Sapena, Nuria Ramirez, Julio Azuaga, Ana Belen Sarmiento, Juan Camilo Cañete, Juan D. Gomez-Puerta, Jose A. Sanmarti, Raimon |
author_sort | Frade-Sosa, Beatriz |
collection | PubMed |
description | Background: We examined whether high-sensitivity CRP (hsCRP) reflected the inflammatory disease status evaluated by clinical and ultrasound (US) parameters in RA patients receiving IL-6 receptor antibodies (anti-IL-6R) or JAK inhibitors (JAKi). Methods: We conducted a cross-sectional study of patients with established RA receiving anti-IL-6R (tocilizumab, sarilumab) or JAKi (tofacitinib, baricitinib). Serum hsCRP and US synovitis in both hands were measured. Associations between hsCRP and clinical inflammatory activity were evaluated using composite activity indices. The association between hsCRP and US synovitis was analyzed. Results: 63 (92% female) patients (42 anti- IL-6R and 21 JAKi) were included, and the median disease duration was 14.4 (0.2–37.5) years. Most patients were in remission or had low levels of disease. Overall hsCRP values were very low, and significantly lower in anti-IL-6R patients (median 0.04 mg/dL vs. 0.16 mg/dL). Anti-IL-6R (82.4%) patients and 48% of JAKi patients had very low hsCRP levels (≤0.1 mg/dL) (p = 0.002). In the anti-IL-6R group, hsCRP did not correlate with the composite activity index or US synovitis. In the JAKi group, hsCRP moderately correlated with US parameters (r = 0.5) but not clinical disease activity, and hsCRP levels were higher in patients with US synovitis (0.02 vs. 0.42 mg/dL) (p = 0.001). Conclusion: In anti-IL-6R RA-treated patients, hsCRP does not reflect the inflammatory disease state, but in those treated with JAKi, hsCRP was associated with US synovitis. |
format | Online Article Text |
id | pubmed-8774492 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-87744922022-01-21 High Sensitivity C Reactive Protein in Patients with Rheumatoid Arthritis Treated with Antibodies against IL-6 or Jak Inhibitors: A Clinical and Ultrasonographic Study Frade-Sosa, Beatriz Ponce, Andrés Ruiz-Esquide, Virginia García-Yébenes, Maria Jesús Morlá, Rosa Sapena, Nuria Ramirez, Julio Azuaga, Ana Belen Sarmiento, Juan Camilo Cañete, Juan D. Gomez-Puerta, Jose A. Sanmarti, Raimon Diagnostics (Basel) Article Background: We examined whether high-sensitivity CRP (hsCRP) reflected the inflammatory disease status evaluated by clinical and ultrasound (US) parameters in RA patients receiving IL-6 receptor antibodies (anti-IL-6R) or JAK inhibitors (JAKi). Methods: We conducted a cross-sectional study of patients with established RA receiving anti-IL-6R (tocilizumab, sarilumab) or JAKi (tofacitinib, baricitinib). Serum hsCRP and US synovitis in both hands were measured. Associations between hsCRP and clinical inflammatory activity were evaluated using composite activity indices. The association between hsCRP and US synovitis was analyzed. Results: 63 (92% female) patients (42 anti- IL-6R and 21 JAKi) were included, and the median disease duration was 14.4 (0.2–37.5) years. Most patients were in remission or had low levels of disease. Overall hsCRP values were very low, and significantly lower in anti-IL-6R patients (median 0.04 mg/dL vs. 0.16 mg/dL). Anti-IL-6R (82.4%) patients and 48% of JAKi patients had very low hsCRP levels (≤0.1 mg/dL) (p = 0.002). In the anti-IL-6R group, hsCRP did not correlate with the composite activity index or US synovitis. In the JAKi group, hsCRP moderately correlated with US parameters (r = 0.5) but not clinical disease activity, and hsCRP levels were higher in patients with US synovitis (0.02 vs. 0.42 mg/dL) (p = 0.001). Conclusion: In anti-IL-6R RA-treated patients, hsCRP does not reflect the inflammatory disease state, but in those treated with JAKi, hsCRP was associated with US synovitis. MDPI 2022-01-13 /pmc/articles/PMC8774492/ /pubmed/35054349 http://dx.doi.org/10.3390/diagnostics12010182 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Frade-Sosa, Beatriz Ponce, Andrés Ruiz-Esquide, Virginia García-Yébenes, Maria Jesús Morlá, Rosa Sapena, Nuria Ramirez, Julio Azuaga, Ana Belen Sarmiento, Juan Camilo Cañete, Juan D. Gomez-Puerta, Jose A. Sanmarti, Raimon High Sensitivity C Reactive Protein in Patients with Rheumatoid Arthritis Treated with Antibodies against IL-6 or Jak Inhibitors: A Clinical and Ultrasonographic Study |
title | High Sensitivity C Reactive Protein in Patients with Rheumatoid Arthritis Treated with Antibodies against IL-6 or Jak Inhibitors: A Clinical and Ultrasonographic Study |
title_full | High Sensitivity C Reactive Protein in Patients with Rheumatoid Arthritis Treated with Antibodies against IL-6 or Jak Inhibitors: A Clinical and Ultrasonographic Study |
title_fullStr | High Sensitivity C Reactive Protein in Patients with Rheumatoid Arthritis Treated with Antibodies against IL-6 or Jak Inhibitors: A Clinical and Ultrasonographic Study |
title_full_unstemmed | High Sensitivity C Reactive Protein in Patients with Rheumatoid Arthritis Treated with Antibodies against IL-6 or Jak Inhibitors: A Clinical and Ultrasonographic Study |
title_short | High Sensitivity C Reactive Protein in Patients with Rheumatoid Arthritis Treated with Antibodies against IL-6 or Jak Inhibitors: A Clinical and Ultrasonographic Study |
title_sort | high sensitivity c reactive protein in patients with rheumatoid arthritis treated with antibodies against il-6 or jak inhibitors: a clinical and ultrasonographic study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8774492/ https://www.ncbi.nlm.nih.gov/pubmed/35054349 http://dx.doi.org/10.3390/diagnostics12010182 |
work_keys_str_mv | AT fradesosabeatriz highsensitivitycreactiveproteininpatientswithrheumatoidarthritistreatedwithantibodiesagainstil6orjakinhibitorsaclinicalandultrasonographicstudy AT ponceandres highsensitivitycreactiveproteininpatientswithrheumatoidarthritistreatedwithantibodiesagainstil6orjakinhibitorsaclinicalandultrasonographicstudy AT ruizesquidevirginia highsensitivitycreactiveproteininpatientswithrheumatoidarthritistreatedwithantibodiesagainstil6orjakinhibitorsaclinicalandultrasonographicstudy AT garciayebenesmariajesus highsensitivitycreactiveproteininpatientswithrheumatoidarthritistreatedwithantibodiesagainstil6orjakinhibitorsaclinicalandultrasonographicstudy AT morlarosa highsensitivitycreactiveproteininpatientswithrheumatoidarthritistreatedwithantibodiesagainstil6orjakinhibitorsaclinicalandultrasonographicstudy AT sapenanuria highsensitivitycreactiveproteininpatientswithrheumatoidarthritistreatedwithantibodiesagainstil6orjakinhibitorsaclinicalandultrasonographicstudy AT ramirezjulio highsensitivitycreactiveproteininpatientswithrheumatoidarthritistreatedwithantibodiesagainstil6orjakinhibitorsaclinicalandultrasonographicstudy AT azuagaanabelen highsensitivitycreactiveproteininpatientswithrheumatoidarthritistreatedwithantibodiesagainstil6orjakinhibitorsaclinicalandultrasonographicstudy AT sarmientojuancamilo highsensitivitycreactiveproteininpatientswithrheumatoidarthritistreatedwithantibodiesagainstil6orjakinhibitorsaclinicalandultrasonographicstudy AT canetejuand highsensitivitycreactiveproteininpatientswithrheumatoidarthritistreatedwithantibodiesagainstil6orjakinhibitorsaclinicalandultrasonographicstudy AT gomezpuertajosea highsensitivitycreactiveproteininpatientswithrheumatoidarthritistreatedwithantibodiesagainstil6orjakinhibitorsaclinicalandultrasonographicstudy AT sanmartiraimon highsensitivitycreactiveproteininpatientswithrheumatoidarthritistreatedwithantibodiesagainstil6orjakinhibitorsaclinicalandultrasonographicstudy |